Evidence map›Paper›PMID 27927930›Full record

ArticleJournal of clinical microbiology2017

Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results.

Jennie H Kwon, Kimberly A Reske, Tiffany Hink, C A Burnham, Erik R Dubberke

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Antibiotics (Basel, Switzerland) · 2022
    Article
  3. Review
  4. The Role of Diagnostic Stewardship inCurrent infectious disease reports · 2020
    Article
  5. South African Society of Clinical MicrobiologySouthern African journal of infectious diseases · 2020
    Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jennie H KwonDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA j.kwon@wustl.edu.
Kimberly A ReskeDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
Tiffany HinkDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.
C A BurnhamDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-1137-840X
Erik R DubberkeDivision of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA.

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Washington University Institute of Clinical and Translational SciencesKL2TR000450 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$8.8M
NCATS NIH HHS KL2 TR000450NCATS NIH HHS UL1 TR000448NCEZID CDC HHS U54 CK000162
6 · The paper itself

Abstract

The objective of this study was to evaluate the clinical characteristics and outcomes of hospitalized patients tested for Clostridium difficile and determine the correlation between pretest probability for C. difficile infection (CDI) and assay results. Patients with testing ordered for C. difficile were enrolled and assigned a high, medium, or low pretest probability of CDI based on clinical evaluation, laboratory, and imaging results. Stool was tested for C. difficile by toxin enzyme immunoassay (EIA) and toxigenic culture (TC). Chi-square analyses and the log rank test were utilized. Among the 111 patients enrolled, stool samples from nine were TC positive and four were EIA positive. Sixty-one (55%) patients had clinically significant diarrhea, 19 (17%) patients did not, and clinically significant diarrhea could not be determined for 31 (28%) patients. Seventy-two (65%) patients were assessed as having a low pretest probability of having CDI, 34 (31%) as having a medium probability, and 5 (5%) as having a high probability. None of the patients with low pretest probabilities had a positive EIA, but four were TC positive. None of the seven patients with a positive TC but a negative index EIA developed CDI within 30 days after the index test or died within 90 days after the index toxin EIA date. Pretest probability for CDI should be considered prior to ordering C. difficile testing and must be taken into account when interpreting test results. CDI is a clinical diagnosis supported by laboratory data, and the detection of toxigenic C. difficile in stool does not necessarily confirm the diagnosis of CDI.

Indexed as

Decision Support TechniquesAdultAgedAged, 80 and overBacterial ToxinsClostridioides difficileClostridium InfectionsDiarrheaFecesFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedProspective StudiesRisk FactorsBacterial ToxinsClostridium difficileClostridium difficile infectionenzyme immunoassay

Identifiers

PMID27927930
PMCPMC5277530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.